|
시장보고서
상품코드
2091265
자가면역질환 치료제 시장 규모, 점유율, 성장 분석 : 약물 계열별, 적응증별, 투여 경로별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)Autoimmune Drugs Market Size, Share, and Growth Analysis, By Drug Class (Tumor Necrosis Factor Inhibitors, Interleukin Inhibitors), By Disease Indication, By Route of Administration, By Distribution Channel, By Region - Industry Forecast 2026-2033 |
||||||
세계의 자가면역질환 치료제 시장 규모는 2024년에 1,305억 달러로 평가되었으며, 2025년 1,385억 9,000만 달러에서 2033년까지 2,242억 5,000만 달러로 확대되어 예측 기간(2026-2033년) 동안 CAGR 6.2%로 성장할 것으로 전망됩니다.
자가면역질환 치료제 세계 시장에는 류마티스 관절염, 다발성 경화증, 건선 등의 질환을 치료하기 위해 면역계에 작용하는 의약품이 포함됩니다. 전 세계 인구의 약 5-8%에 영향을 미치는 자가면역 질환의 유병률 증가는 의료비 급증의 한 요인이 되고 있습니다. 이 시장은 과학의 발전을 원동력으로 삼아, 기존 면역억제제에 중점을 두던 단계에서 바이오의약품 및 바이오시밀러에 대한 관심이 높아지는 단계로 진화하고 있습니다. 이 시장을 견인하는 주요 요인으로는, 고가의 바이오의약품에 대한 환자의 접근성을 높여주는 유리한 보험급여 정책은 물론, 기존 의약품의 적응증 확대를 통해 새로운 수익원이 창출된다는 점을 들 수 있습니다. 또한, AI를 활용한 자동화를 통해 표적 발견, 환자 계층화, 임상시험 등 다양한 측면이 혁신되고, 프로세스의 합리화와 효율화가 진전됨에 따라 이 분야의 혁신과 성장이 촉진되고 있습니다.
세계 자가면역질환 치료제 시장의 성장요인
전 세계적으로 자가면역 질환의 유병률이 증가하고 있는 것이 혁신적인 치료법에 대한 수요를 이끌고 있으며, 이에 따라 제약사들은 연구 개발 노력을 강화하고 있고, 그 결과 신약이 시장에 출시되고 있습니다. 이러한 성장은 자가면역 질환에 대한 인식이 높아지고, 효과적인 치료법에 대한 임상적 필요성이 대두됨에 따라 더욱 가속화되고 있습니다. 의료 종사자들은 보다 종합적인 선별 검사 방법을 도입하고 있으며, 이를 통해 조기 진단이 가능해짐에 따라 이러한 치료법의 혜택을 받을 수 있는 환자층이 확대되고 있습니다. 또한, 환자 지원 단체는 일반 시민의 이해를 높이고, 최첨단 치료법에 대한 수용성을 높이며, 규제 절차의 합리화를 지원하고 있으며, 이 모든 요소가 어우러져 업계 내의 강력한 성장 사이클에 기여하고 있습니다.
세계 자가면역질환 치료제 시장의 제약요인
세계 자가면역질환 치료제 시장은 주로 많은 의약품에 수반되는 높은 비용으로 인해 몇 가지 제약에 직면해 있습니다. 이는 환자와 의료 시스템 양측 모두에게 막대한 경제적 부담을 안겨주는 것입니다. 이러한 경제적 부담은 해당 약물의 광범위한 사용을 제한하고, 보험 급여 확보에 어려움을 초래하며, 궁극적으로는 시장 성장을 저해하고 있습니다. 보험사는 종종 엄격한 처방약 목록 제한을 두고, 보험 적용 승인을 위해 상세한 근거를 요구합니다. 이로 인해 의료 서비스 제공자들은 고가이며 혁신적인 치료법을 처방하는 것을 주저할 가능성이 있습니다. 그 결과, 환자들은 치료를 중단하거나 효과가 낮은 치료법을 선택하게 되며, 이로 인해 최첨단 제품에 대한 수요가 감소하고, 개발 파이프라인의 진전과 장기적인 임상 연구에 대한 투자가 정체될 것입니다.
세계 자가면역질환 치료제 시장의 동향
세계 자가면역질환 치료제 시장은 맞춤형 생물학적 제제 요법의 등장으로 인해 혁신적인 변화를 맞이하고 있습니다. 이러한 치료법은 유전체학 및 바이오마커 연구의 발전에 힘입어 가능해졌으며, 개별 환자의 고유한 프로파일에 맞춰 특정 면역 경로를 표적으로 삼는 데 중점을 두고 있습니다. 이러한 맞춤형 접근은 치료의 유효성과 안전성을 높일 뿐만 아니라, 의료 종사자들이 혁신적인 치료법을 임상 현장에서 더 조기에 도입할 수 있도록 뒷받침하고 있습니다. 또한, 특정 환자 하위 집단에서 입증된 치료 성과를 조건으로 하는 가치 기반 계약이 보험사들 사이에서 점차 받아들여지고 있어, 이러한 정밀 의학에 대한 접근성과 보험 급여가 확대되고 있으며, 그 결과 세계 시장으로의 진출이 가속화되고 있습니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 자가면역질환 치료제 시장 규모 : 약물 계열별
세계의 자가면역질환 치료제 시장 규모 : 질환 적응증별
세계의 자가면역질환 치료제 시장 규모 : 투여 경로별
세계의 자가면역질환 치료제 시장 규모 : 유통 채널별
세계의 자가면역질환 치료제 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSM 26.07.22Global Autoimmune Drugs Market size was valued at USD 130.5 Billion in 2024 and is poised to grow from USD 138.59 Billion in 2025 to USD 224.25 Billion by 2033, growing at a CAGR of 6.2% during the forecast period (2026-2033).
The global market for autoimmune drugs encompasses pharmaceuticals that influence the immune system to address conditions like rheumatoid arthritis, multiple sclerosis, and psoriasis. The increasing prevalence of autoimmune disorders, impacting approximately 5-8% of the global population, significantly contributes to healthcare costs. The market has evolved from a focus on traditional immunosuppressants to a greater emphasis on biologics and biosimilars, fueled by scientific advancements. Key factors driving this market include favorable reimbursement policies that enhance patient access to high-cost biologics, as well as expanded indications for existing medications, which open new revenue avenues. Additionally, AI-driven automation is transforming various aspects, such as target discovery, patient stratification, and clinical trials, streamlining processes and improving efficiency while fostering innovation and growth within the sector.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Autoimmune Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Autoimmune Drugs Market Segments Analysis
Global autoimmune drugs market is segmented by drug class, disease indication, route of administration, distribution channel and region. Based on drug class, the market is segmented into Tumor Necrosis Factor Inhibitors, Interleukin Inhibitors, B-Cell Inhibitors, T-Cell Inhibitors, Immunosuppressants, Corticosteroids, Non-Steroidal Anti-Inflammatory Drugs and Others. Based on disease indication, the market is segmented into Rheumatoid Arthritis, Psoriasis, Multiple Sclerosis, Inflammatory Bowel Disease, Systemic Lupus Erythematosus, Type 1 Diabetes and Others. Based on route of administration, the market is segmented into Oral, Subcutaneous Injection, Intravenous Infusion and Others. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Autoimmune Drugs Market
The rising prevalence of autoimmune diseases worldwide is driving the demand for innovative therapeutic solutions, which encourages pharmaceutical companies to enhance their research and development efforts, resulting in the introduction of new medications to the market. This growth is further propelled by increased awareness of autoimmune disorders and the clinical necessity for effective treatments. Healthcare professionals are implementing more comprehensive screening methods, facilitating earlier diagnostics and expanding the pool of patients who can benefit from these therapies. Additionally, advocacy organizations are improving public knowledge, fostering greater acceptance of cutting-edge treatments, and supporting streamlined regulatory processes, collectively contributing to a robust growth cycle within the industry.
Restraints in the Global Autoimmune Drugs Market
The Global Autoimmune Drugs market faces several restraints primarily due to the high costs associated with many medications, which places a significant financial strain on both patients and healthcare systems. This economic burden limits the widespread use of these drugs and presents challenges in securing reimbursement, ultimately hindering market growth. Insurers frequently implement stringent formulary restrictions, requiring extensive justification for coverage approval, which can dissuade healthcare providers from prescribing more expensive, innovative treatments. As a result, patients may withdraw from therapies or choose less effective options, diminishing demand for cutting-edge products and stalling advancements in the development pipeline and long-term clinical research investments.
Market Trends of the Global Autoimmune Drugs Market
The Global Autoimmune Drugs market is experiencing a transformative trend driven by the emergence of personalized biologic therapies. These therapies focus on targeting specific immune pathways tailored to the unique profiles of individual patients, made possible by advancements in genomics and biomarker research. This tailoring not only enhances treatment efficacy and safety but also encourages healthcare providers to incorporate innovative therapies sooner in clinical practice. Additionally, the increasing acceptance of value-based contracts among payers, contingent upon demonstrated outcomes in specific patient subpopulations, is facilitating broader access and reimbursement for these precision medicines, thus propelling their global market penetration.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Autoimmune Drugs Market Size by Drug Class & CAGR (2026-2033)
- Market Overview
- Tumor Necrosis Factor Inhibitors
- Interleukin Inhibitors
- B-Cell Inhibitors
- T-Cell Inhibitors
- Immunosuppressants
- Corticosteroids
- Non-Steroidal Anti-Inflammatory Drugs
- Others
Global Autoimmune Drugs Market Size by Disease Indication & CAGR (2026-2033)
- Market Overview
- Rheumatoid Arthritis
- Psoriasis
- Multiple Sclerosis
- Inflammatory Bowel Disease
- Crohns Disease
- Ulcerative Colitis
- Systemic Lupus Erythematosus
- Type 1 Diabetes
- Others
Global Autoimmune Drugs Market Size by Route of Administration & CAGR (2026-2033)
- Market Overview
- Oral
- Subcutaneous Injection
- Intravenous Infusion
- Others
Global Autoimmune Drugs Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Autoimmune Drugs Market Size & CAGR (2026-2033)
- North America (Drug Class, Disease Indication, Route of Administration, Distribution Channel)
- US
- Canada
- Europe (Drug Class, Disease Indication, Route of Administration, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Drug Class, Disease Indication, Route of Administration, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Drug Class, Disease Indication, Route of Administration, Distribution Channel)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Drug Class, Disease Indication, Route of Administration, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson Services, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- F. Hoffmann-La Roche Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ucb S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eisai Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Astellas Pharma Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biogen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Incyte Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Horizon Therapeutics plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teijin Pharma Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
